氨磺必利与利培酮治疗男性精神分裂症的临床效果比较

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Amisulpride and Risperidone in male schizophrenia patients.Methods A total of 84 male schizophrenia patients admitted to our hospital from January 2018 to March 2019 were selected as subjects, and divided into the control group (42 cases) and the study group (42 cases) according to the blinded method. The control group was treated with Risperidone, while the study group was treated with Amisulpride. The symptom scores, total effective rate, adverse event rate, emotional situation and quality of life were compared. Results There were no statistically significant differences between the positive syndrome scale score, negative syndrome scale score, psychopathological scale score, positive and negative syndrome scale (PANSS) total score of the two groups before treatment (P＞0.05). The positive syndrome scale score, negative syndrome scale score, psychopathological scale score, and PANSS total score of the two groups after treatment were lower than those before treatment, and the differences were statistically significant (P＜0.05). The positive syndrome scale score, negative syndrome scale score, psychopathological scale score, and PANSS total score of the study group after treatment were lower than those in the control group, and the differences were statistically significant (P ＜0.05). The total effective rate in the study group(92.86%) was higher than that in the control group (78.57%), and the difference was statistically significant (P＜0.05).The overall incidence rate of adverse reactions in the study group (9.52%) was lower than that in the control group(23.81%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences between the self-rating anxiety scale (SAS) and the selfrating depression scale (SDS) of the two groups before treatment (P＞0.05). The SAS and SDS scores of the two groups after treatment were lower than those before treatment,and the differences were statistically significant (P＜0.05). The SAS and SDS scores of the study group after treatment were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference of the quality of life score between the two groups before treatment (P＞0.05). The quality of life scores of the two groups after treatment were higher than those before treatment, and the differences were statistically significant (P＜0.05). The quality of life scores of the study group after treatment was higher than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion Amisulpride can improve the therapeutic effect and the quality of life, effectively control the disease, relieve the disease symptoms, reduce the incidence rate of adverse reactions and promote the fast recovery.

Key words： Amisulpride Risperidone Male schizophrenia Application effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHANG Feng-kun
	HONG Er-lang
	LI Gui-lan
	LI De-sheng
	GAO Hai-long

Cite this article:

CHANG Feng-kun,HONG Er-lang,LI Gui-lan, et al. Clinical effect comparison of Amisulpride and Risperidone in the treatment of male schizophrenia patients[J]. 中国当代医药, 2020, 27(25): 74-77.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I25/74

[1]	董辛.氨磺必利和利培酮治疗精神分裂症的疗效和安全性比较分析[J].北方药学，2018，15（11）：176-177.
[2]	吴徳武，陈晓兰，蒋新伟.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照研究[J].中外医疗，2019，38（6）：106-108.
[3]	胥凤霞.氨磺必利与利培酮治疗精神分裂症的疗效与安全性对比分析[J].中国医药指南，2017，15（22）：8-9.
[4]	刘博文.氨磺必利与利培酮在治疗首发精神分裂症中的疗效和安全性对照分析[J].基层医学论坛，2017，21（25）：3362-3363.
[5]	吕林英.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照分析[J].医药前沿，2018，8（17）：52-53.
[6]	陈凯，钟建明，叶莉军.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照研究[J].海峡药学，2017，29（12）：138-140.
[7]	孙健.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性分析[J].当代医学，2017，23（29）：67-69.
[8]	马英.氨磺必利与利培酮治疗精神分裂症的疗效与安全性分析[J].临床医药文献电子杂志，2016，3（1）：47-48.
[9]	牛学虹.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性临床对比[J].医学理论与实践，2017，30（14）：2076-2078.
[10]	王韵，方贻儒.非典型抗精神病药对男性精神分裂症患者勃起功能及血浆催乳素水平的影响[J].临床精神医学杂志，2018，28（1）：5-7.
[11]	高丽娟，郭华贵，梁震韬，等.阿立哌唑对男性精神分裂症患者继发药源性性功能障碍的影响[J].中华男科学杂志，2017，23（7）：615-619.
[12]	梁海霞，刘珊珊，李芳.利培酮合并氨磺必利致性功能障碍1 例[J].中国医院用药评价与分析，2016，16（2）：283-284.
[13]	张敏，谷伟，邓克文，等.不同抗精神病药物对精神分裂症患者血清性激素水平的影响[J].临床医学研究与实践，2016，1（13）：6-8，14.
[14]	卢华涛.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性[J].系统医学，2019，4（11）：141-143.
[15]	邬俊福，彭红波，张运才.氨磺必利与利培酮治疗精神分裂症疗效及对患者血清PRL 和CRP 水平的影响[J].临床心身疾病杂志，2019，25（2）：29-32.
[16]	易伟华，张良超.氨磺必利与利培酮治疗首发精神分裂症患者的临床效果比较[J].中国处方药，2018，16（11）：13-14.
[17]	崔向波.奥氮平、氨磺必利、利培酮治疗精神分裂症的疗效[J].菏泽医学专科学校学报，2019，31（2）：16-18.
[18]	段侠霞，张燕，张盟，等.非典型抗精神病药对儿童青少年精神分裂症血清甲状腺激素和血脂的影响[J].中国医药导报，2019，16（5）：151-154.
[19]	徐大明，李晖，刘康.齐拉西酮、利培酮治疗精神分裂症的效果及对性激素的影响分析[J].中国医药科学，2020，10（1）：85-87.
[20]	孙洪波，薛欣杰，燕银枝.奥氮平联合氨磺必利治疗难治性精神分裂症的效果研究[J].中国医药科学，2018，8（23）：214-217.